AUTOMA+ 2025 is the fifth edition of the Pharmaceutical Automation and Digitalisation Congress, a closed-door, pre-registered meeting expected to draw 300+ participants in Vösendorf, Austria (Nov. 24–25). The 2025 program focuses on implementations in automation, data integrity/validation (CSA/CSV), AI in operations, and integration across MES/LIMS/ERP/QMS. Launched virtually in 2021 and convened in Zurich in 2024, it has grown into an in-person European forum where pharma/biotech teams and technology providers share implementation experience and discuss regulatory expectations for digital systems.
The 2025 agenda highlights AI and advanced analytics used in day-to-day operations. Program materials list talks from Octapharma (Luuk Seelen, Christophe Chabbert) on machine-learning with sensor data in production; GSK (Cédric Colon) on data-driven supply-chain improvements; and Pfizer (Charis Keramidas) on generative-AI applications inside regulated workflows. The emphasis is on concrete use cases, documentation, validation, and measurement of outcomes.
Sessions also address the mechanics that determine success: data integrity and lineage, computer software assurance/validation (CSA/CSV), electronic records and signatures, change control, and integration across MES/LIMS/ERP/QMS. Case studies and panels examine how organizations align these practices with GMP expectations, including model risk management and audit trails for analytics used in manufacturing and quality.
Program materials also include a Merck KGaA, Darmstadt, Germany session (Thomas Endress) on cyber-physical trust and product traceability, linking physical goods to digital records and maintaining auditability across systems. Roundtables featuring Olivier Melis (argenx) and Akshansh Chaudhary (Venus Remedies) focus on running digital projects under GMP constraints, with discussion of eBR/eLN, PAT for real-time control, and evidence needed to demonstrate systems are fit for purpose.
Filed Under: Drug Discovery and Development, Industry 4.0
